Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

80.19USD
21 Mar 2019
Change (% chg)

$0.25 (+0.32%)
Prev Close
$79.94
Open
$79.45
Day's High
$80.49
Day's Low
$79.32
Volume
2,199,033
Avg. Vol
6,703,944
52-wk High
$80.49
52-wk Low
$56.81

Latest Key Developments (Source: Significant Developments)

New Data for Abbott's HeartMate 3 Highlights Unparalleled Performance of Industry's Leading Heart Pump
Sunday, 17 Mar 2019 11:45am EDT 

March 17 (Reuters) - Abbott Laboratories ::MOMENTUM 3 MET ITS PRIMARY ENDPOINT OF EVENT FREE SURVIVAL WHILE SHOWCASING IMPROVED RATES OF OVERALL SURVIVAL.  Full Article

Roger Bird, Svp Of Abbott Laboratories Reports Open Market Sale Of 9,188 Shares Of Co Priced Between $79.061-$79.0714- SEC Filing
Thursday, 14 Mar 2019 05:15pm EDT 

March 14 (Reuters) - Abbott Laboratories ::ROGER BIRD, SVP OF ABBOTT LABORATORIES REPORTED OPEN MARKET SALE OF 9,188 SHARES OF CO PRICED BETWEEN $79.061-$79.0714 ON MARCH 13 - SEC FILING.  Full Article

FDA Approves New Indication For Abbott's Valve Repair Device
Thursday, 14 Mar 2019 10:59am EDT 

March 14 (Reuters) - FDA::FDA APPROVES NEW INDICATION FOR VALVE REPAIR DEVICE TO TREAT CERTAIN HEART FAILURE PATIENTS WITH MITRAL REGURGITATION.FDA SAYS MITRACLIP CLIP DELIVERY SYSTEM IS MANUFACTURED BY ABBOTT VASCULAR INC..  Full Article

Abbott Laboratories Says Co & Its Unit Redeemed $500 Mln In Aggregate Principal Amount Of Senior Notes - SEC Filing
Monday, 25 Feb 2019 05:42pm EST 

Feb 25 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - ON FEB 24, CO AND ITS UNIT, ST. JUDE MEDICAL, LLC REDEEMED $500 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES - SEC FILING.  Full Article

FDA Approves Device For Treatment Of Premature Babies & Newborns With An Opening In Their Hearts
Monday, 14 Jan 2019 09:00am EST 

Jan 14 (Reuters) - Abbott Laboratories ::FDA APPROVES WORLD'S FIRST DEVICE FOR TREATMENT OF PREMATURE BABIES AND NEWBORNS WITH AN OPENING IN THEIR HEARTS (A COMMON CONGENITAL DEFECT).ABBOTT LABORATORIES - FDA APPROVED AMPLATZER PICCOLO OCCLUDER, A MEDICAL DEVICE THAT CAN BE IMPLANTED IN TINIEST BABIES.  Full Article

Abbott Laboratories Says Projected Sales Greater Than $1 Bln In 2018 For Glucose Monitor Freestyle Libre
Tuesday, 8 Jan 2019 12:31pm EST 

Jan 8 (Reuters) - Abbott Laboratories ::SAYS PROJECTED SALES GREATER THAN $1 BILLION IN 2018 FOR GLUCOSE MONITOR FREESTYLE LIBRE - CONF CALL.SAYS WAS ABLE TO PAYDOWN $8 BILLION DEBT IN THE PAST YEAR THAT CO ASSUMED AFTER ACQUISITIONS - CONF CALL.  Full Article

Abbott Recommends Rejection Of Mini-Tender Offer By Baker Mills
Wednesday, 14 Nov 2018 09:00am EST 

Nov 14 (Reuters) - Abbott Laboratories ::ABBOTT RECOMMENDS REJECTION OF BELOW-MARKET MINI-TENDER OFFER BY BAKER MILLS LLC.ABBOTT LABORATORIES - RECEIVED NOTICE OF UNSOLICITED MINI-TENDER OFFER BY BAKER MILLS TO PURCHASE UP TO 60,000 ABBOTT COMMON SHARES.ABBOTT LABORATORIES - BAKER MILLS' OFFER PRICE OF $57.00 PER SHARE IN CASH.ABBOTT LABORATORIES - OFFER IS CURRENTLY SCHEDULED TO EXPIRE AT 5 P.M. NEW YORK CITY TIME ON MONDAY, DEC. 12, 2018.  Full Article

Abbott Laboratories Recommends Rejection Of Mini-Tender Offer By Baker Mills LLC
Wednesday, 14 Nov 2018 09:00am EST 

Nov 14 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES RECOMMENDS REJECTION OF MINI-TENDER OFFER BY BAKER MILLS LLC.ABBOTT - RECEIVED NOTICE OF UNSOLICITED MINI-TENDER OFFER BY BAKER MILLS LLC TO BUY UP TO 60,000 ABBOTT SHARES, OR SOME 0.003 PERCENT OF OUTSTANDING SHARES.ABBOTT LABORATORIES - BAKER MILLS' OFFER PRICE WAS $57.00 PER SHARE IN CASH.  Full Article

Abbott Introduces The Next Generation Of Influenza A & B And Strep A Assays With Fastest-Ever Time To Molecular Results
Thursday, 25 Oct 2018 09:00am EDT 

Oct 25 (Reuters) - Abbott Laboratories ::ABBOTT INTRODUCES THE NEXT GENERATION OF INFLUENZA A & B AND STREP A ASSAYS WITH FASTEST-EVER TIME TO MOLECULAR RESULTS.  Full Article

Abbott Unit Intends To Offer Senior Unsecured Notes
Wednesday, 19 Sep 2018 06:47am EDT 

Sept 19 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - UNIT OF CO INTENDS TO OFFER SENIOR UNSECURED NOTES IN OFFERING.ABBOTT - TO USE PROCEEDS TO REFINANCE ALL/PORTIONS OF OUTSTANDING 2.00% NOTES DUE 2020, 4.125% NOTES DUE 2020, AMONG OTHERS - SEC FILING.  Full Article

U.S. joins case against Abbott's Alere over diabetic tests

The U.S. Justice Department on Tuesday said it has joined a whistleblower lawsuit alleging Abbott Laboratories' Alere Inc unit defrauded Medicare into paying for unnecessary testing supplies for diabetic patients.